Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced XXXX .

@entity901 @entity4181 @entity1 @entity137 @entity390 @entity1261 @entity294 @entity900 @entity391 @entity1503 @entity1398 @entity1205 @entity356 @entity1487
UNASSIGNED: The aim of this study was to retrospectively compare the efficacy and @entity137 of the @entity901 + @entity1487 ( @entity1487 ) + @entity4181 (LV) regimen [modified (m)FOLFOX-6] with that of the @entity1205 + @entity900 + @entity1487 regimen (DCF) in @entity1 with advanced @entity356 (AGC). A total of 72 @entity1 received DCF (75 mg/m(2) @entity1205 and 75 mg/m(2) @entity900 on day 1 and 750 mg/m(2) @entity1487 on days 1-5) every 21 days, whereas 54 @entity1 received mFOLFOX-6 (85 mg/m(2) @entity901 and 400 mg/m(2) LV as a 2-h infusion, followed by a @entity1487 bolus of 400 mg/m(2) and 2,400 mg/m(2) @entity1487 as a 46-h continuous infusion) every 14 days. In the DCF arm, 55 (76.4%) of the @entity1 received prophylactic @entity1261 ( @entity1261 ), 48-72 h following completion of chemotherapy. The median follow-up of the study was 12.1 months. The overall response rate (ORR) was 37.0% for mFOLFOX-6 and 40.3% for DCF (P=0.72). The median time to progression was 6.5 and 6.2 months in the mFOLFOX-6 and DCF arms, respectively (P=0.70). The median overall survival was 11.4 and 13.5 months in the mFOLFOX-6 and DCF arms, respectively (P=0.72). The rates of @entity1503 did not differ between the two arms. However, in the subgroup analysis, grade 3-4 @entity1398 and @entity1398 were significantly more common among @entity1 who had not received @entity1261 prophylaxis in the DCF arm. The incidence of grade 3-4 @entity390 / @entity391 and @entity294 were significantly higher in the DCF arm. In conclusion, the present study demonstrated that the efficacy of the mFOLFOX-6 regimen was comparable to that of the DCF regimen in AGC @entity1 . In addition, the benefit of @entity1261 prophylaxis in conjunction with the DCF regimen was demonstrated.
